Novartis Reports Patients with Aggressive Form of Melanoma Lived Average of Two+ Years When Taking Tafinlar + Mekinist

Novartis NVS today announced updated data from the Phase III COMBI-v study showing a significant overall survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) compared to vemurafenib monotherapy. The combination also demonstrated significant health-related quality of life improvements in the trial, including overall health, physical and social functioning. Results are being presented at the European Cancer Congress 2015 in Vienna. "It is remarkable to see so See full press release